SYGNIS AG successfully completes Rights Offering and Private Placement
(Thomson Reuters ONE) -
SYGNIS AG /
SYGNIS AG successfully completes Rights Offering and Private Placement
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Heidelberg, Germany, October 28, 2013 - SYGNIS AG (Frankfurt: LIO1; ISIN:
DE000A1RFM03, Prime Standard) today announced that the Company has successfully
completed its rights offering. The subscription price was ? 2.65 per share. New
shares that were not subscribed in the course of the rights offering by existing
shareholders were offered to selected German and international institutional
investors in a private placement at a purchase price equivalent to the
subscription price. In the transaction 1,019,309 new shares against cash were
subscribed.
The Management Board, with the approval of the Supervisory Board, has resolved
to increase the Company's share capital from ? 9,364,258.00 to ? 10,383,567.00
by issuing 1,019,309 new shares. The offering utilizes existing authorized
capital created by resolution at the Annual General Meeting on August 28, 2013.
The new shares carry full dividend rights as of January 1, 2013.
"We welcome our new shareholders and are very thankful for their trust in the
new business direction of SYGNIS," stated Pilar de la Huerta, CEO and CFO of
SYGNIS AG. "SYGNIS is a key player in the fast growing market of DNA
amplification and sequencing. With the first commercial agreement around SYGNIS'
core technology QualiPhi(®) with QIAGEN, the world leading provider of sample
and assay technologies and a full pipeline with potential blockbuster products
for next generation sequencing applications, SYGNIS is best positioned to
benefit from the high growth rates we are seeing in gene-based personalized
healthcare, molecular diagnostics and epigenetics. The transaction is in our
view in the best interest of the Company and its shareholders as it provides the
Company with the financial flexibility needed to further execute on its business
plans and closes the gap to break-even expected in 2014."
SYGNIS plans to use the gross proceeds of EUR 2.7 million to finance its
operating business and further growth.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Tel: +34-918063089
Email: pdelahuerta(at)sygnis.es
About SYGNIS AG: www.sygnis.com
After the merger in 2012 between X-Pol Biotech, specialising in DNA
amplification and sequencing, and SYGNIS AG, listed in the German Stock Exchange
(Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS' new mission is
to develop and distribute technologies and products from X-Pol, which has a
commercial product in the DNA amplification segment, QualiPhi(®) and is
currently developing other products in the field of Next Generation Sequencing.
### Disclaimer
This publication is intended for information only and constitutes neither an
offer to sell nor an invitation to buy securities. Some statements included in
this press release, relating neither to proven financial results nor other
historical data, should be viewed as forward-looking, i.e. not definite. Such
statements are mainly predictions of future results, trends, plans or goals.
These statements should not be considered to be total guarantees since given
their very nature they are subject to known and unknown risks and
imponderability and can be affected by other factors as a consequence of which
the actual results, plans and goals of SYGNIS AG may deviate greatly from the
established conclusions or implied predictions contained in such statements.
SYGNIS does not undertake to publicly update or revise these statements in the
light of new information or future results or for any other reason.###
Press Release (PDF):
http://hugin.info/150277/R/1738493/583181.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: SYGNIS AG via Thomson Reuters ONE
[HUG#1738493]
Unternehmensinformation / Kurzprofil:
Datum: 28.10.2013 - 09:35 Uhr
Sprache: Deutsch
News-ID 309739
Anzahl Zeichen: 4951
contact information:
Town:
Heidelberg
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 143 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"SYGNIS AG successfully completes Rights Offering and Private Placement"
steht unter der journalistisch-redaktionellen Verantwortung von
SYGNIS AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
